FEELM
1.7.2022 10:09:09 CEST | Business Wire | Press release
Industry and Information Technology Bureau of Shenzhen Municipality announced the list of the second batch of industrial design development support program in 2022. SMOORE, along with Shenzhen Skyworth, DJI and other technology companies were shortlisted.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220701005128/en/
The industrial design development support program supports the recognized industrial design centers or industrial design team of enterprises with strong innovation capabilities, design distinctiveness, and key competencies.
Meanwhile, the Industry and Information Technology Bureau of Shenzhen Municipality requests the shortlisted parties to lead and support both the advanced manufacturing and prevailing traditional industries with industrial design capability. Ultimately, enterprises shall achieve improvements in four aspects: external appearance, friendly user experience, branding and quality assurance, further to convert the improvements to deployment.
The public information of the shortlist announcement discloses that in-house industrial design team of FEELM, the flagship atomization tech brand of SMOORE wins the recognition out of its "innovative design and achievement transformation of closed-pod electronic atomizer based on leadless ceramic heating technology."
FEELM industrial design team has created a number of design works that combine technological attributes, practicality and consumer caring, empowering FEELM’s electronic atomization solution to connect consumer experience with advanced smart manufacturing.
From 2020 to 2022, FEELM industrial design team has won 8 prestige International design awards including the Red Dot Award, the iF Design Award, the German National Design Award and the MUSE Design Award.
In 2022, 4 product designs of FEELM won Red Dot Product Design Award, known as the "Oscar" of global industrial design at once. Among it, the vape design inspired from the design ingenuity of lipstick, which the nozzle can be twisted to hide the mouthpiece from getting on dusts receives positive feedbacks due to the clean and hygiene product experience it brings.
Another awarded product design is FEELM eco-friendly disposable e-cigarette. Its external structure is composed of recyclable and reusable aluminum foil. It looks like a paper foil pouch and itself serves as a packaging bag, hence to reduce the excessive consumption of packaging materials.
Meanwhile, one of the key competencies of FEELM – the automation capacity can ensure mass production of innovative, design-led products, to be further launched in global consumer market through FEELM’s global business partners.
As a global leading vaping tech brand, the industrial design concepts presented by FEELM is not only own manifestation of social responsibility, but also a shorthand to show brand innovation capabilities, R&D investment, talent construction, and business performance.
The head of FEELM Industrial design team, Totom Lu says, "FEELM design devotes to helping clients in improving user experience from the perspective of vaping tech brand, keep pushing it to the new heights. I think the future direction of design of closed-pod vaping solution should lean on 3 dimensions: product experience; emotional experience, which is to identify problems before users notice them and sustainable experience, to focus on product sustainability."
About FEELM:
As a flagship tech brand belonging to SMOORE, FEELM is the world’s leading closed vape system solution provider. Based on the world's leading Ceramic Coil Heating Technology, FEELM combines authentic Flavor Reproduction Technology with innovative electronics technology, bringing ultimate sensation and premium vaping experience.
About SMOORE:
SMOORE is a global leader in offering vaping technology solutions, including manufacturing vaping devices, and vaping components for HNB products on an ODM basis, with advanced R&D technology, strong manufacturing capacity, wide-spectrum product portfolio and diverse customer base.
According to Frost & Sullivan, SMOORE is the world’s largest vaping device manufacturer in terms of revenue, accounting for 22.8% of the total global market share, in 2021. Its global market share is bigger than the sum of those listed from No.2 to No.5.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220701005128/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom